Five-year outcomes of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation

Five-year outcomes of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation

Not available.

Saved in:

Bibliographic Details
Main Authors:	Shuangyou Liu, Lihong An, Zhichao Yin, Yuehui Lin, Zhuojun Ling, Biping Deng, Xinjian Yu, Qinlong Zheng, Defeng Zhao, Tong Wu, Alex H. Chang, Chunrong Tong
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2024-12-01
Series:	Haematologica
Online Access:	https://haematologica.org/article/view/11872
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia
by: Tingting Yang, et al.
Published: (2025-01-01)

Deletion of CD38 enhances CD19 chimeric antigen receptor T cell function
by: Kimberly Veliz, et al.
Published: (2024-06-01)

An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk
by: Bin Xue, et al.
Published: (2025-01-01)

Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma
by: Xiaodan Luo, et al.
Published: (2024-12-01)

Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma
by: Narendranath Epperla, et al.
Published: (2025-01-01)

Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma
by: Andrew D. Hughes, et al.
Published: (2025-01-01)

Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults
by: Maike Breidenbach, et al.
Published: (2025-01-01)

Chimeric antigen receptor T cells targeting CD312 as a therapy for acute myeloid leukemia
by: Danni Xie, et al.
Published: (2025-01-01)

Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy
by: Alexander P. Boardman, et al.
Published: (2024-11-01)

Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22
by: Scott McComb, et al.
Published: (2024-03-01)

Immunoinformatics Approach to Design a Chimeric CD70-Peptide Vaccine against Renal Cell Carcinoma
by: Haideh Namdari, et al.
Published: (2024-01-01)

A preclinical study of allogeneic CD19 chimeric antigen receptor double‐negative T cells as an off‐the‐shelf immunotherapy drug against B‐cell malignancies
by: Dan Wang, et al.
Published: (2024-01-01)

Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy
by: Prashant Ramesh Tembhare, et al.
Published: (2020-05-01)

CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?
by: Marie José Kersten, et al.
Published: (2025-01-01)

Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia
by: Veronika Mancikova, et al.
Published: (2020-05-01)

Adenosine-Induced NLRP11 in B Lymphoblasts Suppresses Human CD4+ T Helper Cell Responses
by: Irem Ozel, et al.
Published: (2020-01-01)

CD19‐targeting chimeric antigen receptor T‐cell therapy is safe and effective for intra‐cardiac B cell non‐Hodgkin lymphoma
by: Daniel H. Chen, et al.
Published: (2024-12-01)

CD4+ T cell-derived IL-22 enhances liver metastasis by promoting angiogenesis
by: Tao Zhang, et al.
Published: (2023-12-01)

Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers
by: Pablo Menendez, et al.
Published: (2022-12-01)

T-Cell Lymphoblastic Leukemia/Lymphoma: Relapse 16 Years after First Remission
by: Lauren Elreda, et al.
Published: (2014-01-01)

Retracted: Role of CD4+T, CD8+T Cells, and CD4+T/CD8+T Cell Ratio in Gastric Cancer and Its Clinical Significance
by: Applied Bionics and Biomechanics
Published: (2023-01-01)

The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis
by: Jile Liu, et al.
Published: (2025-01-01)

Case report: The case of T-cell acute lymphoblastic leukemia treated with chemotherapy followed by anti-CD7 CAR-T cells using retroviral vector
by: Huanhuan Zhou, et al.
Published: (2025-01-01)

Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
by: Dina M Flink, et al.
Published: (2024-03-01)

Single-cell landscape of dynamic changes in CD8+ T cells, CD4+ T cells and exhausted T cells in hepatocellular carcinoma
by: Rongqiang Liu, et al.
Published: (2025-02-01)

Downregulation of CD4+LAP+ and CD4+CD25+ Regulatory T Cells in Acute Coronary Syndromes
by: Ying-zhong Lin, et al.
Published: (2013-01-01)

Ex Vivo Restimulation of Human PBMC Expands a CD3+CD4-CD8-γδ+ T Cell Population That Can Confound the Evaluation of CD4 and CD8 T Cell Responses to Vaccination
by: B. J. Sedgmen, et al.
Published: (2013-01-01)

Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study)
by: Annemarie Glöckner, et al.
Published: (2025-01-01)

Diagnostic Value of CD25, CD69, and CD134 on Tuberculosis-Specific Antigen-Stimulated CD4+ T Cells for Tuberculous Pleurisy
by: Hanlu Shi, et al.
Published: (2023-01-01)

MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
by: Elena Maino, et al.
Published: (2015-01-01)

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
by: Haiying Qin, et al.
Published: (2021-09-01)

Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy
by: Barbara D. Friedes, et al.
Published: (2025-01-01)

Clinical and prognostic significance of CD27 and CD44 expression patterns in Egyptian pediatric patients with B-precursor acute lymphoblastic leukemia
by: Asmaa Abobakr, et al.
Published: (2024-12-01)

Tag7 (PGLYRP1) Can Induce an Emergence of the CD3+CD4+CD25+CD127+ Cells with Antitumor Activity
by: T. N. Sharapova, et al.
Published: (2018-01-01)

Key role of CD4+ T cells in determining CD8 function during CAR-T cell manufacture
by: J Joseph Melenhorst, et al.
Published: (2024-03-01)

CD22 modulation alleviates amyloid β-induced neuroinflammation
by: Yu Dong Mai, et al.
Published: (2025-02-01)

Infiltration and subtype analysis of CD3 + CD20 + T cells in lung cancer
by: Liping Luo, et al.
Published: (2025-01-01)

The Story of CD4+CD28− T Cells Revisited: Solved or Still Ongoing?
by: Kathrin Maly, et al.
Published: (2015-01-01)

Study on the Stability of Unpackaged CdS/CdTe Solar Cells with Different Structures
by: Guanggen Zeng, et al.
Published: (2019-01-01)

The Regulation between CD4+CXCR5+ Follicular Helper T (Tfh) Cells and CD19+CD24hiCD38hi Regulatory B (Breg) Cells in Gastric Cancer
by: Ying Zhang, et al.
Published: (2022-01-01)